A study evaluating the different treatment modalities for EGFR mutation positive advanced NSCLC patients that acquire c-MET amplification after EGFR TKI therapy resistant

被引：0
|
作者：
Qu, J. [1 ]
Liu, L. [2 ]
Heng, J. [2 ]
Zhou, C. [2 ]
Xiong, Y. [2 ]
Jiang, W. [2 ]
Yang, N. [2 ]
机构：
[1] Hunan Prov Canc Hosp, Dept Lung Canc & Gastroenterol, Changsha, Hunan, Peoples R China
[2] Hunan Prov Tumor Hosp, Changsha, Hunan, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
133P
引用
收藏
页码：51 / 51
页数：1
相关论文
共 50 条
  • [1] Crizotinib treatment for patients with EGFR mutation positive NSCLC that acquire cMET amplification after EGFR TKI therapy results in short-lived and heterogeneous responses
    van Veggel, Bianca
    de Langen, Adrianus J.
    Hashemi, Sayed
    Monkhorst, Kim
    Rosenberg, Efraim H.
    Heideman, Danielle A. M.
    Radonic, Teodora
    Smit, Egbert F.
    LUNG CANCER, 2018, 124 : 130 - 134
  • [2] Observational study of rebiopsy in EGFR-TKI-resistant patients with EGFR mutation-positive advanced NSCLC
    Kenichi Koyama
    Satoru Miura
    Satoshi Watanabe
    Satoshi Shoji
    Jun Koshio
    Yoshiki Hayashi
    Daisuke Ishikawa
    Ko Sato
    Takao Miyabayashi
    Masaaki Okajima
    Takeshi Ota
    Tomohiro Tanaka
    Naoya Matsumoto
    Hideyuki Kuriyama
    Tetsuya Abe
    Koichiro Nozaki
    Kosuke Ichikawa
    Rie Kondo
    Hiroshi Tanaka
    Toshiaki Kikuchi
    Scientific Reports, 12
  • [3] Observational study of rebiopsy in EGFR-TKI-resistant patients with EGFR mutation-positive advanced NSCLC
    Koyama, Kenichi
    Miura, Satoru
    Watanabe, Satoshi
    Shoji, Satoshi
    Koshio, Jun
    Hayashi, Yoshiki
    Ishikawa, Daisuke
    Sato, Ko
    Miyabayashi, Takao
    Okajima, Masaaki
    Ota, Takeshi
    Tanaka, Tomohiro
    Matsumoto, Naoya
    Kuriyama, Hideyuki
    Abe, Tetsuya
    Nozaki, Koichiro
    Ichikawa, Kosuke
    Kondo, Rie
    Tanaka, Hiroshi
    Kikuchi, Toshiaki
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [4] Clinical Characteristics of Patients With MET Amplification-Positive NSCLC After EGFR-TKI Therapy
    Lee, J. H.
    Ahn, B.
    Kim, M. H.
    Pyo, K.
    Lee, C.
    Lim, S. M.
    Hong, M. H.
    Kim, H. R.
    Cho, B. C.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1145 - S1146
  • [5] T790M mutation and c-MET amplification might be correlated to TTP of EGFR-TKI in NSCLC
    Wu, Y.
    Mok, T. S.
    Chen, H.
    Zhang, X.
    Guo, A.
    Jaenne, P. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [6] Targeting HER2-and MET co-amplification in patients with EGFR mutation resistant to EGFR-TKI therapy
    Brandes, V
    Scheffler, M.
    Kambartel, K.
    Ortiz-Cuaran, S.
    Scheel, A.
    Michels, S.
    Nogova, L.
    Fischer, R.
    Abdulla, D.
    Merkelbach-Bruse, S.
    Buettner, R.
    Sos, M. L.
    Wolf, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 172 - 172
  • [7] Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study
    Wenxian Wang
    Hong Wang
    Peihua Lu
    Zongyang Yu
    Chunwei Xu
    Wu Zhuang
    Zhengbo Song
    Journal of Translational Medicine, 17
  • [8] Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study
    Wang, Wenxian
    Wang, Hong
    Lu, Peihua
    Yu, Zongyang
    Xu, Chunwei
    Zhuang, Wu
    Song, Zhengbo
    JOURNAL OF TRANSLATIONAL MEDICINE, 2019, 17 (1)
  • [9] Comparison of EGFR-TKI and chemotherapy in the first-line treatment of advanced EGFR mutation-positive NSCLC
    Fiala, O.
    Pesek, M.
    Finek, J.
    Benesova, L.
    Bortlicek, Z.
    Minarik, M.
    NEOPLASMA, 2013, 60 (04) : 425 - 431
  • [10] Time to EGFR-TKI Treatment for Patients with Advanced NSCLC and EGFR Activating Mutation in a Tertiary Cancer Center
    Le Guevelou, Jennifer
    Dugue, Audrey
    Richard, Nicolas
    Dubos, Catherine
    Do, Pascal
    Danhier, Serge
    Lerouge, Delphine
    Bonneau, Jessica
    Blanc, Cecile
    Gervais, Radj
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1229 - S1229
12345